Search Results

November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc The successful completion of this Phase 1 safety program will enable centers in Japan to be included

and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics Inc (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed

May 2022 "MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. Vraniak served as the Chief Financial Officer of electroCore, Inc. and was a key member of the management Vraniak served as an executive in various innovative healthcare and technology companies including GE

October 2022 Increased Anxiety-like Behaviors in Adgra1-/- Male But Not Female Mice are Attributable expressed in the brain, suggesting that Adgra1 may be involved in the regulation of neurological behaviors including

October 2022 Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism

For decades, GPCR localization relied on: Antibodies of inconsistent specificity Fixed tissue sections matter most Clarify brain vs. peripheral contributions to metabolic therapy Guide how next-generation incretin

disease and obesity This shift also aligned Hodson’s work with a major scientific wave: The rise of incretin-based produced fluorescent GPCR tools  that allow researchers to visualize GPCR engagement in live tissues , including Should patients stay on incretin therapies for life?

GPCR Podcast: Visualizing GLP-1 & GIP Receptors in Islets and Brain Understanding incretin biology depends The result is a clearer view of how incretin-based therapies act in complex metabolic environments. Why this matters Receptor distribution shapes incretin hormone drug effects across islets and neural GPCR University courses returning next year and platform capabilities expanding, Premium pricing will increase FAQ 🔹 What’s included?

March 2022 "February 17, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO & SHANGHAI- ShouTi Inc., a

August 2022 "CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc.

December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and Trevena Inc. could offer potential new weapons against omicron and future viral variants. Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants, including

Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc

July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical

R-Bridge Healthcare Fund, an affiliate of CBC Group "CHESTERBROOK, Pa., March 31, 2022 -- Trevena, Inc

volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK, Pa., Dec. 13, 2021 - Trevena, Inc

connection with the Collaboration and License Agreement (“License Agreement”) with Neurocrine Biosciences, Inc

development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc

Royalty-Based Financing with R-Bridge Healthcare Fund "CHESTERBROOK, Pa., April 18, 2022 - Trevena, Inc

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics, Inc., a venture-backed clinical stage GPCR just had a very successful first meeting including all the Scientific Advisory Board."

2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals, Inc

September 2022 "The function of the actin cytoskeleton in cellular motility and trafficking has been widely studied. However, reorganization of the actin cytoskeleton upon modulation of membrane cholesterol and its consequences on membrane dynamics are addressed only rarely. In a recent work, we reported that chronic cholesterol depletion using statins leads to significant polymerization of the actin cytoskeleton. In this work, we explore the effect of reorganization of the actin cytoskeleton on membrane dynamics under cholesterol-depleted condition. Specifically, we explore the role of actin cytoskeleton in regulating the dynamics of the serotonin1A receptor, a crucial neurotransmitter G protein-coupled receptor (GPCR) that plays a major role in the generation and modulation of cognitive and behavioral functions. For this, we analyzed the lateral dynamics of the serotonin1A receptor in cholesterol-depleted cells (using statins) by fluorescence recovery after photobleaching (FRAP) and fluorescence loss in photobleaching (FLIP) measurements. Our results indicate that lateral diffusion parameters of serotonin1A receptors in normal cells are consistent with models describing the diffusion of molecules in a homogeneous membrane. Interestingly, these parameters are altered in cholesterol-depleted cells and the receptor exhibits dynamic confinement. Notably, our results show that statin-induced dynamic confinement could be reversed by destabilization of the actin cytoskeleton. On a broader perspective, these results assume significance in understanding the modulatory role of the membrane environment on the organization and dynamics of GPCRs in diseases caused by altered cholesterol biosynthesis." Read more at the source #DrGPCR #GPCR #IndustryNews

Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals, Inc

Metabolic Syndrome in Phase 1B Clinical Trial "MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc.

Patricia Drake appointed new Chief Commercial Officer CHESTERBROOK, Pa., Nov. 11, 2021 -- Trevena, Inc

EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics, Inc

today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc

Products for Human Use (CHMP) "SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc

years of age and older) Patients with Classic CAH SAN DIEGO, June 13, 2022 -- Neurocrine Biosciences, Inc

Financing Provided by 5AM and Frazier – Pipeline is Built from Crinetics’ Core Nonpeptide Platform and Includes Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals, Inc